IGC Pharma

04/23/2026

Kerwin Medical Center in Dallas, Texas has been added as a clinical site in IGC Pharma’s Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s disease, which has reached approximately 80% enrollment.

The site is led by Dr. Alka Khera, a behavioral neurologist with experience in Alzheimer’s clinical trials, supporting both patient recruitment and clinical ex*****on as the study progresses toward enrollment completion.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-adds-kerwin-medical-123000687.html

04/21/2026

IGC Pharma has received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development facility in Bogotá. This allows the Company to explore potential applications of psilocybin in neuropsychiatric symptoms (NPS) associated with dementia.

NPS affect approximately 80% of patients with Alzheimer’s disease and are broad and heterogeneous, including agitation, depression, anxiety, and mood-related conditions. While IGC-AD1 continues advancing through a Phase 2 clinical trial targeting agitation associated with Alzheimer’s disease, the Company believes that differentiated mechanisms may be required across these symptom clusters, creating the potential for multiple therapeutic pathways.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-secures-psilocybin-research-123000764.html

04/16/2026

Alzheimer’s disease impacts both patients and caregivers alike. Agitation is one of its most common and challenging symptoms, often placing significant emotional and practical strain on families.

Addressing agitation remains a critical unmet medical need. At IGC Pharma, we are developing investigational therapeutic approaches designed to target agitation associated with Alzheimer’s disease through rigorous and responsible clinical development.

Watch the full video here:
https://www.youtube.com/watch?v=PPY2CKHMUzE

IGC Pharma is developing innovative therapies focused on reducing agitation in Alzheimer’s patients, one of the most challenging and disruptive symptoms of t...

04/16/2026

Understanding changes in memory or cognition can bring uncertainty, but having clear information can help families feel more grounded as they move forward.

Early conversations with healthcare professionals can provide direction, open access to resources, and support thoughtful decision-making along the way.

Awareness is not about fear. It’s about preparation, support, and knowing that help is available.


This information is for general educational purposes only and does not replace professional medical advice. Consult a healthcare professional for personalized guidance.

04/15/2026

Reaching ~80% patient enrollment, IGC Pharma continues progressing its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease.

The study, a randomized, double-blind, placebo-controlled trial, is now entering its final phase of recruitment across its U.S. and Canadian clinical network, with enrollment completion expected in mid-2026.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-reaches-80-enrollment-123000503.html

04/14/2026

Alzheimer’s disease is more than memory loss, it can also involve behavioral symptoms such as agitation that deeply affect patients and caregivers. In a recent interview on New to The Street, IGC Pharma CEO Ram Mukunda discusses what happens in the brain in Alzheimer’s, the human impact of agitation, and the progress of the Phase 2 CALMA trial evaluating IGC-AD1.

Watch the full interview here: https://www.youtube.com/watch?v=1qG4yD7DoWA

IGC Pharma is advancing a promising Phase 2 clinical trial targeting agitation in Alzheimer’s patients, with enrollment already over 70% complete. The compan...

04/08/2026

Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.25 per share.

All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/ascendiant-capital-markets-raises-igc-164500647.html

04/07/2026

On World Health Day, conversations about global health often focus on infectious disease and emerging threats. Yet Alzheimer’s disease continues to rise steadily across aging populations worldwide.

As more families are affected, gaps in diagnosis, caregiver support, and access to research remain; especially in regions with limited healthcare infrastructure.

Addressing Alzheimer’s growing burden requires more than new therapies. It calls for stronger systems, better-connected data, and research that reaches more communities.

Progress in global health depends on building solutions that are scalable, equitable, and designed to serve patients and caregivers everywhere.

04/07/2026

Tandem Clinical Research, a Prolerity Network site, in Metairie, Louisiana has been activated as part of the ongoing Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s disease.

The site is led by Dr. Angela Traylor, an experienced neurologist and psychiatrist, supported by a clinical trial coordination team with expertise in patient engagement and clinical operations management.

With enrollment now over 70% complete, the study continues to expand its geographic reach and patient access.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-adds-tandem-clinical-120000020.html?guccounter=1

03/31/2026

To enhance visibility across investor audiences, IGC Pharma has partnered with New to The Street, a financial media platform known for its integrated investor engagement and national television distribution.

The campaign will feature IGC Pharma on New to The Street’s sponsored programming on Fox Business and Bloomberg Television and will be amplified through digital channels, outdoor billboard placements, and earned media distribution across major U.S. broadcast affiliates.

The Company believes participation in such platforms supports broader market awareness while maintaining a focus on disciplined clinical ex*****on and scientific development.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-launches-strategic-national-120000699.html

03/26/2026

The CALMA Clinical Trial team recently joined the Autumn Is Here podcast hosted by Francine Crawford, a platform dedicated to supporting caregivers and raising awareness around aging and Alzheimer’s disease.

Barbara Forero, Clinical Recruitment Coordinator, and Margarita Venegas, Psychometric Training & Site Feasibility Manager, shared insights into the purpose of the CALMA clinical trial, its focus on agitation in Alzheimer’s disease, participant safety, and what researchers hope to learn through ongoing studies.

We’re grateful for the opportunity to connect with caregiver communities and contribute to thoughtful conversations around Alzheimer’s research.

Listen to the full episode here: https://www.youtube.com/watch?v=uXguYFQb08I

03/20/2026

Today at AD/PD - Advances in Science & Therapy 2026, the IGC Pharma AI team presented aha™ (Agentic Harmonization Assistant) at the Alzheimer's Disease Data Initiative (ADDI) booth.

aha™ is designed to address one of the core challenges in Alzheimer’s research: integrating fragmented datasets across institutions and modalities. By harmonizing tabular and neuroimaging data, it supports cross-cohort analysis and AI-ready research at scale.

We are proud to collaborate with ADDI, reflecting a shared commitment to scalable, interoperable data solutions for the global research community.

aha™ was recently recognized as a semifinalist in the Alzheimer’s Insights AI Prize, a global initiative by ADDI to accelerate AI-driven discovery.

Strengthening research infrastructure is essential to advancing Alzheimer’s science.